Feature

Psychedelic therapeutics has become one of the most talked about ways to treat specific mental health issues, overcoming a long history of misconceptions thanks to increasing clinical evidence of their effectiveness in treating ailments such as addiction and PTSD. In fact, studies conducted in jurisdictions where legalized use of medically controlled psychedelic compounds such as psilocybin, ketamine, and MDMA have shown effectiveness in treating disorders that even conservative doctors and politicians are calling for expedited studies to evaluate their use

Despite weak markets, Avalon GloboCare (NASDAQ: ALBT) stock has been able to defend its valuation. Except for a late-day blip on Tuesday, ALBT shares have been consolidating at the $3.40 level, which from current prices and ALBT having enough accretive ammo to reclaim consolidation levels, puts an 11% gain in investors’ crosshairs. Of course, long-term investors expect and want more, and with a series of partnerships, successful financing completed, and a recap to shares leaving only about 3.22 million outstanding,

Safe-T Group Ltd. has been busy on the business stage and on Tuesday announced its corporate rebranding to better reflect its position in a surging cybersecurity sector. Starting yesterday, the company is identified as Alarum Technologies Ltd. (NASDAQ, TASE: ALAR) with the word “alarum” derived from the Latin word for “warning,” which the company notes better reflects its corporate vision, core values, and commitment to providing advanced privacy and cybersecurity solutions. That commitment is also a mission in progress. Over

Siyata Mobile (NASDAQ: SYTA) stock is on a bullish run, with shares higher by over 73% YTD following a 11% spike on Wednesday. To those following SYTA, the move is not surprising. In fact, many will argue the jump is well-deserved from being on time to capitalize on a more than $20 billion market opportunity. But more than “on-time,” SYTA supporters point to the company doing things differently than its competitors, with 21st-century technology providing more than a competitive advantage,

Weakness in Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) stock is less a trend than it is an opportunity. In fact, the decline in value over the past two weeks may be well overdone, noting that a series of milestones reached, patents earned, and valuable partnerships ideally position CMND to have its best year in 2023.  Driving that proposition is Clearmind Medicine nearing its goal of delivering a first-to-market psychedelic-based treatment to market, with its lead candidate, MEAI, targeting a

It pays to be different in crowded sectors, and Siyata Mobile (NASDAQ: SYTA) is proving that point. In fact, SYTA’s standout characteristics have been instrumental in the pursuit of its mission to secure a global market leadership position in the fast-growing Push-to-Talk Over Cellular (PoC) sector. Thus, don’t be misled by the company’s micro-cap share price; SYTA is performing in the major leagues of the industry and is disrupting traditional Land Mobile Radio (LMR) markets with next-generation cellular technology. SYTA